1. Home
  2. CKPT vs CNTB Comparison

CKPT vs CNTB Comparison

Compare CKPT & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CKPT
  • CNTB
  • Stock Information
  • Founded
  • CKPT 2014
  • CNTB 2012
  • Country
  • CKPT United States
  • CNTB United States
  • Employees
  • CKPT N/A
  • CNTB N/A
  • Industry
  • CKPT Biotechnology: Pharmaceutical Preparations
  • CNTB Biotechnology: Pharmaceutical Preparations
  • Sector
  • CKPT Health Care
  • CNTB Health Care
  • Exchange
  • CKPT Nasdaq
  • CNTB Nasdaq
  • Market Cap
  • CKPT N/A
  • CNTB 68.5M
  • IPO Year
  • CKPT 2017
  • CNTB 2021
  • Fundamental
  • Price
  • CKPT $3.77
  • CNTB $1.17
  • Analyst Decision
  • CKPT Strong Buy
  • CNTB Strong Buy
  • Analyst Count
  • CKPT 2
  • CNTB 1
  • Target Price
  • CKPT $12.00
  • CNTB $8.00
  • AVG Volume (30 Days)
  • CKPT 946.5K
  • CNTB 24.6K
  • Earning Date
  • CKPT 11-11-2024
  • CNTB 09-05-2024
  • Dividend Yield
  • CKPT N/A
  • CNTB N/A
  • EPS Growth
  • CKPT N/A
  • CNTB N/A
  • EPS
  • CKPT N/A
  • CNTB N/A
  • Revenue
  • CKPT $78,000.00
  • CNTB $24,116,000.00
  • Revenue This Year
  • CKPT N/A
  • CNTB N/A
  • Revenue Next Year
  • CKPT $151,162.55
  • CNTB $63.90
  • P/E Ratio
  • CKPT N/A
  • CNTB N/A
  • Revenue Growth
  • CKPT N/A
  • CNTB N/A
  • 52 Week Low
  • CKPT $1.36
  • CNTB $0.68
  • 52 Week High
  • CKPT $3.95
  • CNTB $2.84
  • Technical
  • Relative Strength Index (RSI)
  • CKPT 84.67
  • CNTB 44.02
  • Support Level
  • CKPT $2.37
  • CNTB $1.18
  • Resistance Level
  • CKPT $2.54
  • CNTB $1.26
  • Average True Range (ATR)
  • CKPT 0.27
  • CNTB 0.07
  • MACD
  • CKPT 0.10
  • CNTB -0.01
  • Stochastic Oscillator
  • CKPT 88.60
  • CNTB 13.59

About CNTB Connect Biopharma Holdings Limited

Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.

Share on Social Networks: